253 related articles for article (PubMed ID: 28219927)
1. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.
Smeenk L; Fischer M; Jurado S; Jaritz M; Azaryan A; Werner B; Roth M; Zuber J; Stanulla M; den Boer ML; Mullighan CG; Strehl S; Busslinger M
EMBO J; 2017 Mar; 36(6):718-735. PubMed ID: 28219927
[TBL] [Abstract][Full Text] [Related]
2. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.
Cazzaniga V; Bugarin C; Bardini M; Giordan M; te Kronnie G; Basso G; Biondi A; Fazio G; Cazzaniga G
Oncotarget; 2015 Jan; 6(3):1569-81. PubMed ID: 25595912
[TBL] [Abstract][Full Text] [Related]
3. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
4. Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.
van der Weyden L; Giotopoulos G; Wong K; Rust AG; Robles-Espinoza CD; Osaki H; Huntly BJ; Adams DJ
BMC Cancer; 2015 Aug; 15():585. PubMed ID: 26269126
[TBL] [Abstract][Full Text] [Related]
5. A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
Ha J; Kim B; Hahn S; Lee ST; Lyu CJ; Choi JR
Ann Hematol; 2018 Aug; 97(8):1505-1507. PubMed ID: 29520434
[No Abstract] [Full Text] [Related]
6. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
7. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
8. PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5.
Fazio G; Cazzaniga V; Palmi C; Galbiati M; Giordan M; te Kronnie G; Rolink A; Biondi A; Cazzaniga G
Leukemia; 2013 Apr; 27(4):992-5. PubMed ID: 23090680
[No Abstract] [Full Text] [Related]
9. Loss of Pax5 Exploits Sca1-BCR-ABL
Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
[TBL] [Abstract][Full Text] [Related]
10. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
11. FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia.
Put N; Deeren D; Michaux L; Vandenberghe P
Cancer Genet; 2011 Aug; 204(8):462-4. PubMed ID: 21962897
[TBL] [Abstract][Full Text] [Related]
12. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
13. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.
Zhou MH; Gao L; Jing Y; Xu YY; Ding Y; Wang N; Wang W; Li MY; Han XP; Sun JZ; Wang LL; Yu L
Ann Hematol; 2012 Aug; 91(8):1235-43. PubMed ID: 22373549
[TBL] [Abstract][Full Text] [Related]
14. A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia.
Yang YL; Yen CT; Pai CH; Chen HY; Yu SL; Lin CY; Hu CY; Jou ST; Lin DT; Lin SR; Lin SW
PLoS One; 2015; 10(11):e0142863. PubMed ID: 26580398
[TBL] [Abstract][Full Text] [Related]
15. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
[TBL] [Abstract][Full Text] [Related]
16. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
[TBL] [Abstract][Full Text] [Related]
17. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
18. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E; van Emst L; Yuniati L; van Ingen Schenau D; Gerritsen M; van der Meer LT; Williams O; Hoogerbrugge PM; Scheijen B; van Leeuwen FN
Exp Hematol; 2018 Apr; 60():57-62.e3. PubMed ID: 29408281
[TBL] [Abstract][Full Text] [Related]
20. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia.
Kim M; Choi JE; She CJ; Hwang SM; Shin HY; Ahn HS; Yoon SS; Kim BK; Park MH; Lee DS
Blood Cells Mol Dis; 2011 Jun; 47(1):62-6. PubMed ID: 21549623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
